Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2603-2606
JournalEuropean Journal of Cancer
Volume47
Issue number17
DOIs
Publication statusPublished - 2011

Cite this